Pfizer and Valneva's Lyme disease vaccine has shown promising results in clinical trials, paving the way for regulatory approval despite setbacks due to fewer cases than expected, according to the companies.
Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial
